Quick Answer
LIGAND PHARMACEUTICALS INC reported Operating Income Loss of $41.00 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +281.4% in Operating Income Loss from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), LIGAND PHARMACEUTICALS INC's Operating Income Loss has grown by 511.4%.
- Historical annual values: Fiscal year 2025: $41.00 million | Fiscal year 2024: -$22.61 million | Fiscal year 2023: $11.94 million | Fiscal year 2022: $3.04 million | Fiscal year 2021: $103.85 million | Fiscal year 2020: $37.50 million | Fiscal year 2019: $807.08 million | Fiscal year 2018: $163.73 million | Fiscal year 2017: $68.08 million | Fiscal year 2016: $43.89 million | Fiscal year 2015: $27.33 million | Fiscal year 2014: $19.63 million | Fiscal year 2013: $14.94 million | Fiscal year 2012: $193.0 thousand | Fiscal year 2011: -$878.0 thousand | Fiscal year 2010: -$29.30 million | Fiscal year 2009: -$9.97 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: